DMAC vs EMN · $157.4M cap vs P/E 21, rev $9.38B
DiaMedica Therapeutics Inc (DMAC) versus Eastman Chemical Company (EMN) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Eastman Chemical Company (EMN) is a specialty chemicals company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported EMN revenue for 2024-12-31 was $9.38B. Net income was $908.0M. Revenue was up 1.9% from 2023-12-31 to 2024-12-31. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
DMAC currently screens at market cap $157.4M. EMN currently screens at market cap $8.21B and trailing P/E 20.8.
Not investment advice. Open the DMAC and EMN stock pages for the full models.
Not investment advice.